CDK4 and breast carcinoma: In breast cancer, it was reported that when combined AIs with novel targeted drugs such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, the PFS of patients was significantly increased.15 However, there is no similar study in USs.